Review of mifamurtide in the treatment of patients with osteosarcoma

References

• MirabelloLTroisiRJSavageSAOsteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results ProgramCancer20091151531154319197972
   PubMed Web of Science ®Google Scholar
• MirabelloLTroisiRJSavageSAInternational osteosarcoma incidence patterns in children and adolescents, middle ages and elderly personsInt J Cancer2009125122923419330840
   PubMed Web of Science ®Google Scholar
• MeyersPAMuramyl tripeptide (mifamurtide) for the treatment of osteosarcomaExpert Rev Anticancer Ther200991035104919671023
   PubMed Web of Science ®Google Scholar
• KagerLZoubekAPotschgerUPrimary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocolsJ Clin Oncol2003212011201812743156
   PubMed Web of Science ®Google Scholar
• Kempf-BielackBBielackSSJurgensHOsteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)J Clin Oncol20052355956815659502
   PubMed Web of Science ®Google Scholar
• BielackSSKempf-BielackBDellingGPrognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocolsJ Clin Oncol20022077679011821461
   PubMed Web of Science ®Google Scholar
• BielackSSKempf-BielackBBranscheidDSecond and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patientsJ Clin Oncol20092755756519075282
   PubMed Web of Science ®Google Scholar
• PicciPSangiorgiLRougraffBTRelationship of chemotherapy-induced necrosis and surgical margins to local recurrence in osteosarcomaJ Clin Oncol199412269927057989947
   PubMed Web of Science ®Google Scholar
• MoriKAndoKHeymannDLiposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastasesExpert Rev Anticancer Ther2008815115918279055
   PubMed Web of Science ®Google Scholar
• AndersonPLiposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcomaFuture Oncol2006233334316787112
   PubMedGoogle Scholar
• NardinALefebvreMLLabroquereKLiposomal muramyl tripeptide phosphatidylethanolamine: targeting and activating macrophages for adjuvant treatment of osteosarcomaCurr Cancer Drug Targets2006612313316529542
   PubMed Web of Science ®Google Scholar
• BalkwillFTumour necrosis factor and cancerNat Rev Cancer2009936137119343034
   PubMed Web of Science ®Google Scholar
• GeddesKMagalhaesJGGirardinSEUnleashing the therapeutic potential of NOD-like receptorsNat Rev Drug Discov2009846547919483708
   PubMed Web of Science ®Google Scholar
• ShawMHReimerTKimYGNOD-like receptors (NLRs): bona fide intracellular microbial sensorsCurr Opin Immunol20082037738218585455
   PubMed Web of Science ®Google Scholar
• Marina-GarciaNFranchiLKimYGPannexin-1-mediated intracellular delivery of muramyl dipeptide induces caspase-1 activation via cryopyrin/NLRP3 independently of Nod2J Immunol20081804050405718322214
   PubMed Web of Science ®Google Scholar
• SoneSMutsuuraSOgawaraMPotentiating effect of muramyl dipeptide and its lipophilic analog encapsulated in liposomes on tumor cell killing by human monocytesJ Immunol1984132210521106699409
   PubMed Web of Science ®Google Scholar
• FidlerIJBrownNOHartIRSpecies variability for toxicity of free and liposome-encapsulated muramyl peptides administered intravenouslyJ Biol Response Mod198542983094020387
   PubMedGoogle Scholar
• MurrayJLKleinermanESCunninghamJEPhase I trial of liposomal muramyl tripeptide phosphatidylethanolamine in cancer patientsJ Clin Oncol19897191519252479721
   PubMed Web of Science ®Google Scholar
• LandmannRObristRDenzHPharmacokinetics and immunomodulatory effects on monocytes during prolonged therapy with liposomal muramyltripeptideBiotherapy199371128068481
   PubMedGoogle Scholar
• FidlerIJBarnesZFoglerWEInvolvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activatorsCancer Res1982424965017055801
   PubMed Web of Science ®Google Scholar
• FidlerIJPosteGMacrophage-mediated destruction of malignant tumor cells and new strategies for the therapy of metastatic diseaseSpringer Semin Immunopathol198251611746755782
   PubMed Web of Science ®Google Scholar
• KleinermanESJiaSFGriffinJPhase II study of liposomal muramyl tripeptide in osteosarcoma: the cytokine cascade and monocyte activation following administrationJ Clin Oncol199210131013161634921
   PubMed Web of Science ®Google Scholar
• AsanoTKleinermanESLiposome-encapsulated MTP-PE: a novel biologic agent for cancer therapyJ Immunother Emphasis Tumor Immunol1993142862928280710
   PubMed Web of Science ®Google Scholar
• SerugaBZhangHBernsteinLJCytokines and their relationship to the symptoms and outcome of cancerNat Rev Cancer2008888789918846100
   PubMed Web of Science ®Google Scholar
• MeyersPASchwartzCLKrailoMDOsteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology GroupJ Clin Oncol20082663363818235123
   PubMed Web of Science ®Google Scholar
• HobohmUFever therapy revisitedBr J Cancer20059242142515700041
   PubMed Web of Science ®Google Scholar
• JeysLMGrimerRJCarterSRPost operative infection and increased survival in osteosarcoma patients: are they associatedAnn Surg Oncol2007142887289517653803
   PubMed Web of Science ®Google Scholar
• MacEwenEGKurzmanIDRosenthalRCTherapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptideJ Natl Cancer Inst1989819359382733037
   PubMed Web of Science ®Google Scholar
• KurzmanIDMacEwenEGRosenthalRCAdjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatinClin Cancer Res19951159516019815961
   PubMed Web of Science ®Google Scholar
• KurzmanIDShiFVailDMIn vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cellsCancer Biother Radiopharm19991412112810850295
   PubMed Web of Science ®Google Scholar
• CreavenPJCowensJWBrennerDEInitial clinical trial of the macrophage activator muramyl tripeptide-phosphatidylethanolamine encapsulated in liposomes in patients with advanced cancerJ Biol Response Mod199094924982254761
   PubMedGoogle Scholar
• KleinermanESGanoJBJohnstonDAEfficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcomaAm J Clin Oncol19951893997900714
   PubMed Web of Science ®Google Scholar
• KleinermanESMeyersPARaymondAKCombination therapy with ifosfamide and liposome-encapsulated muramyl tripeptide: tolerability, toxicity, and immune stimulationJ Immunother Emphasis Tumor Immunol1995171811937613644
   PubMed Web of Science ®Google Scholar
• ChouAJKleinermanESKrailoMDAddition of muramyl tri-peptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children‘s Oncology GroupCancer20091155339534819637348
   PubMed Web of Science ®Google Scholar
• MeyersPASchwartzCLKrailoMOsteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexateJ Clin Oncol2005232004201115774791
   PubMed Web of Science ®Google Scholar
• HunsbergerSFreidlinBSmithMAComplexities in interpretation of osteosarcoma clinical trial resultsJ Clin Oncol20082631033104 author reply 3104310518565905
   PubMed Web of Science ®Google Scholar
• BielackSSMarinaNFerrariSOsteosarcoma: the same old drugs or more?J Clin Oncol20082631023103; author reply 3104310518565904
   PubMed Web of Science ®Google Scholar
• MeyersPASchwartzCLKrailoMIn replyJ Clin Oncol2008261831043105
   Web of Science ®Google Scholar